Which companies are Kuros Biosciences's closest peers?

The cockpit's peer set: Shenzhen YHLO Biotech (688575.SS), Shantou Institute of Ultrasonic Instruments (301602.SZ), Beijing Hotgen Biotech (688068.SS), Eckert & Ziegler (EUZ.DE), Xiangyu Medical (688626.SS), Caina Technology (301122.SZ), HOB Biotech (688656.SS), Artivion (AORT).

Is Kuros Biosciences expensive compared with its peers?

On forward p/e it trades at 73.8× against a peer median of 23.6×, 3rd most expensive of 16 in its peer set.

How has Kuros Biosciences stock performed?

Over six months to 6 Nov 2026 the shares returned +2.8% against -18.7% for the median peer; over one year -35.3%.

← CockpitCompetitor Analysis › KURN.SW Kuros Biosciences Ltd.Open in the cockpit ↗

Kuros Biosciences Ltd.KURN.SWCompetitor analysis, valuation and peers

Switzerland · CHF·Health Care›Medical Specialties

Momentum weak 27

Competitor Analysis ▸ Charts Open in the cockpit

Mkt cap

$953M

US dollars, full cap

Free float

72%

of shares outstanding

$/day

$6.21M

20-day average traded

Fwd P/E

73.8×

forward earnings

ROIC−WACC

+3.9 pp

WACC 5.0%

Hurdle

n/a

no reverse DCF

Next earnings

117 days

3 Mar 2027

Close · CHFCHF 19.54

1D-5.3%

1W-5.3%

1M+8.6%

3M-15.3%

6M+2.8%

YTD-28.9%

1Y-35.3%

ATR %5.7%

52w lowhigh39.8% off high

What Kuros Biosciences does

Employees: 178

Kuros Biosciences at a glance

Size Kuros Biosciences (KURN.SW) is a Switzerland Health Care company (Medical Specialties) with a market value of $953M, the 122nd largest of 158 Switzerland companies the cockpit tracks. Shares closed at CHF 19.54 on 6 Nov 2026.

Performance Over six months the shares gained 2.8%, against -18.7% for the median peer and +11.6% for the Switzerland market (cap-weighted) — 6th highest of 21 in its peer set.

Growth Revenue grew 40.9% over the last twelve months (peer median +4.1%); the operating margin is 6.0% (peer median 9.0%).

Valuation It trades at 73.8× forward earnings against a peer median of 23.6× (3rd most expensive of 16).

Capital Return on invested capital runs 3.9 points above its cost of capital (5.0% WACC).

Next results Next results expected around 3 Mar 2027 (exchange calendar; dates can move).

Relative performance

Six months, rebased to 100: Kuros Biosciences against the median of its 20 peers (local-currency closes).

Kuros Biosciences financials

Reported figures in CHF; fiscal year ends 2025-12-31. TTM = trailing twelve months.
	TTM	FY2025	FY2024	FY2023	FY2022
Revenue	CHF 139M	CHF 121M	CHF 75.0M	CHF 33.6M	CHF 18.0M
Revenue growth	—	+62%	+123%	+87%	—
Gross profit	CHF 118M	CHF 105M	CHF 65.9M	CHF 27.8M	CHF 13.8M
EBITDA	CHF 11.6M	CHF 10.1M	CHF 2.61M	-CHF 2.58M	-CHF 7.37M
Net income	CHF 7.12M	CHF 2.12M	-CHF 4.26M	-CHF 13.7M	-CHF 14.6M
Free cash flow	-CHF 6.61M	-CHF 2.40M	CHF 2.03M	-CHF 9.16M	-CHF 7.74M
Capital expenditure	CHF 6.32M	CHF 2.03M	CHF 1.10M	CHF 326,000	CHF 400,000
Total debt	n/a	CHF 3.94M	CHF 4.92M	CHF 5.52M	CHF 7.72M

Quarterly statements and history in the cockpit →

Kuros Biosciences competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

Up and to the right = strong over both horizons. Kuros Biosciences is the large dot.

Fundamentals: revenue growth against valuation

Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Kuros Biosciences is the large dot.

Kuros Biosciences competitors and peer comparison

How Kuros Biosciences compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Kuros Biosciences against its 20 peers (data as of 6 Nov 2026)
Measure	KURN.SW	Peer median	Rank in peer set
1-month return	+8.6%	-4.8%	5th highest of 21
6-month return	+2.8%	-18.7%	6th highest of 21
Distance from 52-week high	-39.8%	-38.8%	11th highest of 21
Revenue growth (TTM)	+40.9%	+4.1%	2nd highest of 21
Operating margin	6.0%	9.0%	7th lowest of 21
Forward P/E	73.8×	23.6×	3rd most expensive of 16
ROIC minus cost of capital	+3.9 pp	+1.1 pp	7th highest of 20
EV / EBITDA	67.6×	10.3×	most expensive of 9
Net debt / EBITDA	0.3×	-1.4×	3rd most indebted of 9

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
Company	Market	Market cap	6M return	Revenue growth	Op. margin	Forward P/E	Req g	Delivered g
Kuros Biosciences KURN.SW	Switzerland	$953M	+3%	+41%	6%	73.8×	n/a	n/a
Shenzhen YHLO Biotech 688575.SS	China	$950M	-20%	+3%	12%	37.2×	3.1%	+12.7%
Shantou Institute of Ultrasonic Instruments 301602.SZ	China	$944M	-19%	+4%	30%	n/a	13.1%	+4.6%
Beijing Hotgen Biotech 688068.SS	China	$966M	-38%	+8%	-94%	n/a	n/a	n/a
Eckert & Ziegler EUZ.DE	Germany	$969M	-7%	+4%	25%	17.0×	7.2%	+12.1%
Xiangyu Medical 688626.SS	China	$969M	-31%	0%	4%	62.1×	n/a	n/a
Caina Technology 301122.SZ	China	$938M	+60%	+61%	0%	72.0×	n/a	n/a
HOB Biotech 688656.SS	China	$972M	-22%	+6%	7%	188.9×	40.1%	+12.4%
Artivion AORT	United States	$985M	-20%	+16%	7%	3,912.9×	n/a	n/a
Aidite (Qinhuangdao) Technology 301580.SZ	China	$919M	-20%	+17%	18%	27.1×	19.9%	+23.3%
Castle Biosciences CSTL	United States	$993M	+64%	+3%	-9%	n/a	n/a	n/a
Seegene 096530.KS	South Korea	$915M	+26%	+12%	13%	15.9×	-3.4%	-15.9%
Ningbo Jansen Superconducting Technologies 688805.SS	China	$915M	-30%	+36%	14%	n/a	47.2%	+17.1%
LifeTech Scientific 1302.HK	Hong Kong	$914M	-18%	+1%	12%	23.5×	13.3%	+15.5%
Beijing SDL Technology 002658.SZ	China	$910M	-21%	-13%	9%	23.6×	18.0%	+2.9%
Shanghai Runda Medical Technology 603108.SS	China	$909M	-25%	-12%	-2%	25.1×	22.2%	-0.2%
Mani 7730.T	Japan	$909M	-15%	+10%	30%	18.4×	1.5%	+13.9%
Bioventus BVS	United States	$894M	+1%	+4%	10%	13.1×	6.9%	+12.1%
Safilo SFL.MI	Italy	$890M	+24%	-4%	9%	16.0×	-0.5%	+4.7%
Cisen Pharmaceutical 603367.SS	China	$890M	-15%	-6%	8%	8.3×	-12.9%	-1.3%
Ceribell CBLL	United States	$1.03B	+32%	+31%	-70%	n/a	n/a	n/a

Questions

Which companies are Kuros Biosciences's closest peers?: The cockpit's peer set: Shenzhen YHLO Biotech (688575.SS), Shantou Institute of Ultrasonic Instruments (301602.SZ), Beijing Hotgen Biotech (688068.SS), Eckert & Ziegler (EUZ.DE), Xiangyu Medical (688626.SS), Caina Technology (301122.SZ), HOB Biotech (688656.SS), Artivion (AORT).
Is Kuros Biosciences expensive compared with its peers?: On forward p/e it trades at 73.8× against a peer median of 23.6×, 3rd most expensive of 16 in its peer set.
How has Kuros Biosciences stock performed?: Over six months to 6 Nov 2026 the shares returned +2.8% against -18.7% for the median peer; over one year -35.3%.